Systems and methods for lysosome induced immunogenic cell death

A lysosomal membrane and antibody technology, applied in the direction of anti-animal/human immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody, etc., can solve the problem of high mortality of cancer patients

Pending Publication Date: 2020-10-16
ANTIGENESIS LLC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although cancer can be treated using techniques such as radiation therapy, surgery, chemotherapy, or ta

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systems and methods for lysosome induced immunogenic cell death
  • Systems and methods for lysosome induced immunogenic cell death
  • Systems and methods for lysosome induced immunogenic cell death

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] The generation of neoantigens is a step in the development of immunogenic cell death (ICD). Lysosomes contain various degradative enzymes, including proteases, glycosidases, and phosphatases. If released into the cytoplasm, these enzymes degrade intracellular material and, in the process, may generate neoantigens. These neoantigens are then taken up by dendritic cells and macrophages. These dendritic cells and macrophages migrate to the lymph nodes, where neoantigens activate T and B cells, which then lead to cell death by activating the adaptive immune system.

Embodiment 2

[0080] In this prophetic embodiment, a composition comprising a complex and an enzyme is provided for a human subject having a tumor, wherein the complex comprises an antibody that recognizes the tumor. In some cases, the antibody is a commercially available antibody, such as a tumor recognizing antibody or a monoclonal antibody.

[0081] This enzyme is an enzyme that causes lysosomal leakage, which can lead to the production of antigens. In this embodiment, the enzyme is an oxidase that generates reactive oxygen species, which damages or ruptures the lysosome and causes it to leak. Oxidases are capable of generating reactive oxygen species, such as superoxide. In this embodiment, the oxidase is xanthine oxidase.

[0082] The xanthine oxidase is covalently complexed to the antibody and administered intravenously or intramuscularly to the subject. When the antibody targets the tumor, the enzyme reacts with the lysosome, causing damage or rupture, which produces the antigen a...

Embodiment 3

[0084] In this prophetic example, the human subject was treated as in Example 2, but in addition the subject received a regimen of deactivation and / or reduction of antioxidants that may May interfere with the action of the compound. In one example, the subject is provided with an unsaturated fatty acid, such as CH 2 =CHCOOH. Fatty acids can inhibit the action of antioxidants, causing a greater response of the complex.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention generally relates to systems and methods for treating cancer using immunogenic cell death, e.g., lysosome-induced immunogenic cell death. This includes at least three aspects, which may be used separately or together. A first aspect involves the preparation of a tumor for treatment, for example, by withdrawal and suppression of antioxidants, supply of n-3 through n-6 and other unsaturated fatty acids, and/or treatment of the subject with statins. A second aspect involves restoration of p53 functionality through genetic manipulation, including techniques involving CRISPR.A third aspect involves constructing an antibody-enzyme complex where the antibody recognizes the tumor and the enzyme is an oxidase. The complex may be administered to a subject. The subject may alsobe provided with a substrate to the enzyme. These and/or other aspects, may be used separately or together, and may be used to treat and/or cure cancer. In some cases, the lysosome may be targeted ininducing cell death, e.g., in cancer cells.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Patent Application No. 62 / 587,207, filed on November 16, 2017, with the inventor E. Fossel, and the title of the invention is "A Lysosome-Induced Apoptosis Cancer Therapeutic Method", and the October 2018 Priority to U.S. Provisional Patent Application No. 62 / 740,477, entitled "System and Method for Inducing Apoptosis to Treat Cancer," Inventor Fossel, filed April 3, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention generally relates to systems and methods for treating cancer using immunogenic cell death. For example, certain embodiments of the invention aim to cause lysosome-induced immunity by targeting lysosomes, causing their lysosomal membranes to become permeable and leak degradative enzymes, leading to internal digestion leading to apoptosis Primary cell death, thereby treating and / or curing cancer. Background tech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28C07K16/30C12N9/02C12N9/04A61K39/395A61K38/43A61K38/44A61P35/04
CPCC07K16/30A61P35/04A61K47/6815A61K47/6851A61K38/443A61K2300/00A61P35/00A61K31/20A61K31/40A61K38/44
Inventor 埃里克·T·福塞尔
Owner ANTIGENESIS LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap